Editorial
|
|
|
|
|
The case for independence
|
|
|
|
New Products
|
|
|
|
|
Just another immunosuppressant for multiple sclerosis
|
|
|
|
|
|
|
|
|
|
|
|
Choose the fixed-dose lopinavir + ritonavir combination
|
|
|
|
|
|
|
|
|
|
No long-term advantage in macular oedema following retinal vein occlusion
|
|
|
|
|
|
|
|
|
|
A sixth alpha-1 blocker for urological indications: no better than the rest
|
|
|
|
|
|
|
|
|
|
4 more grass species, but still no progress
|
|
|
|
|
|
Adverse Effects
|
|
|
|
|
Beware SSRI antidepressants
|
|
|
|
|
|
|
|
|
|
Unbalancing the harm-benefit balance
|
|
|
|
|
|
|
|
|
|
Drug and non-drug related
|
|
|
|
Reviews
|
|
|
|
|
Little efficacy but few adverse effects: a fairly positive harm-benefit balance
|
|
|
|
|
|
|
|
|
|
Adverse effects of ivabradine confirmed
|
|
|
|
|
|
Outlook
|
|
|
|
|
Good news for health professionals and patients
|
|
|
|
|
|
|
|
|
|
Fewer than 1 in 8 of prescribed drugs
|
|
|
|
|
|
|
|
|
|
Taxation could be an option
|
|
|
|
|
|
|
|
|
|
Kaplan-Meier and actuarial methods
|
|
|
|
|
|
|
|